Intestinal Microbiome Post-Azythromycin/Albendazole Treatment
NCT ID: NCT03032042
Last Updated: 2021-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2017-01-31
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
NCT03570814
Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya
NCT02397772
Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation
NCT00130910
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
NCT01192802
Relative Efficacy of Two Regimens of Ante-helminthic Treatment
NCT00367627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
albendazole at day 0, azithromycin at day 7
Albendazole
azithromycin at day 0, albendazole at day 7
Azithromycin
albendazole at day 0, azithromycin at day 0
Azithromycin
Albendazole
Delayed treatment
albendazole at day 7, azithromycin at day 7
Delayed treatment
Albendazole+Azithromycin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azithromycin
Albendazole
Delayed treatment
Albendazole+Azithromycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* refusal of parent/guardian
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeremy Keenan, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
F.I. Proctor Foundation, University of California San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Carter Center Ethiopia
Addis Ababa, , Ethiopia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-0101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.